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Abstract
Background: The international nasopharynx cancer (NPC) burdens are masked due to the lack of integrated studies that
examine epidemiological data based on up-to-date international disease databases such as the Cancer Information (CIN)
databases provided by the International Agency for Research on Cancer (IARC).
Methods: By analyzing the most recently updated NPC epidemiological data available from IARC, we tried to retrieve the
worldwide NPC burden and patterns from combined analysis with GLOBOCAN2008 and the Cancer Incidence in Five
Continents (CI5) databases. We provide age-standardized rates (ASR) for NPC mortality in 20 highest cancer registries from
GLOBOCAN2008 and the World Health Organization (WHO) mortality databases, respectively. However, NPC incidence data
can not be retrieved since it is not individually listed in CI5 database. The trend of NPC mortality was investigated with
Joinpoint analysis in the selected countries/regions with high ASR.
Results: GLOBOCAN 2008 revealed that the highest NPC incidence rates in 2008 were in registries from South-Eastern Asia,
Micronesia and Southern Africa with Malaysia, Indonesia and Singapore ranking the top 3. WHO mortality database analysis
revealed that China Hong Kong, Singapore and Malta ranks the top 3 regions with the highest 5-year mortality rates.
Conclusions: NPC mortality rate is about 2–3 times higher in male than that in female, and shows decrease tendency in
those selected countries/regions during the analyzed periods. However, the integrated analyses of the current IARC CIN
databases may not be suitable to retrieve epidemiological data of NPC. Much effort is required to improve the local cancer
entry and regional death-reporting systems so as to aid similar studies.
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Introduction
Nasopharyngeal cancer (NPC) is a specific cancer with ethnic
and geographic distributions; its etiology is far from being
completely understood. NPC is rare in most parts of the world,
where incidences of age standardized rates (ASR) are generally
below 1 per 100,000 person-years [1,2]. However, in some well-
defined populations, including natives of southern China,
Southeast Asia, the Arctic and the Middle East/North Africa,
NPC is a leading form of cancer [1,2,3]. The distinctive racial/
ethnic and geographic distribution of NPC suggests that both
environmental factors and genetic traits contribute to its develop-
ment. To elucidate their impacts on the incidence as well as
mortality, it is necessary to figure out the worldwide tendency of
NPC. However, the international variations in NPC are masked
because of the lack of integrated studies that examine not only
incidence but also mortality data based on up-to-date international
disease database. Thus, we tried to describe the global incidence
and mortality patterns of NPC by using the most recent data
available from the International Agency for Research on Cancer
(IARC).
IARC is part of the World Health Organization (WHO).
Various databases containing information on the global occur-
rence of cancer were held and managed by the Section of Cancer
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‘‘CANCERMondial (http://www-dep.iarc.fr/)’’. The CIN data-
bases available for the current study include: GLOBOCAN,
Cancer Incidence in Five Continents (CI5) and WHO mortality
databases. Each database covers some specific aspects and an
integrated view of a specific cancer is expected to be achieved via
combined analyses of these databases. Furthermore, these data can
be abstracted for off-line analysis as well as being analyzed with
IARC’s online analysis tools. GLOBOCAN2008 provides access
to the most recent estimates (for 2008) of the incidence of, and
mortality from 28 major cancers all over the world [4]. CI5
provides access to detailed information on the incidence of cancer
recorded by global cancer registries (regional or national). WHO
mortality database presents long time series of selected cancer
mortality recorded in selected countries. The world-wide tenden-
cies for rectal cancer has been investigated based on the integrated
analyses of these databases, which confirmed their usefulness in
similar study [5].
As a specific cancer type with racial/ethnic and geographic
distribution, we had expected that the worldwide variation of NPC
can be investigated via the integrated analyses of these databases.
But there are differences in the number of data entries, recording
periods, and cancer classifying protocols among 3 databases,
which can significantly affect the analytic output. For example, the
code for NPC according to the International Classification of
Diseases for Oncology (ICD-O) is C11. In CI5, this code is not
individually listed, thus, we could not use CI5 database to retrieve
incidence rate and tendency during the observing period.
However, in GLOBOCAN2008 and WHO mortality databases,
C11 is individually listed so that estimation of mortality rate and
tendency can be achieved.
Based on the above-mentioned limitations, we performed the
current study for two purposes: first, whether the integrated
analyses of IARC CIN databases can be used to provide the global
variations of NPC; second, if yes, how accurate is the output and
what can be improved to get more accurate output.
Methods
National level contemporary estimates of the incidence of, and
mortality from NPC are collected from GLOBOCAN2008 project
that presents latest data for 2008. Cancer incidence data are
compiled and provided by IARC in volumes I to IX of CI5 by
world-wide population-based cancer registries at the national or
regional levels. The most recent volume of CI5 (volume IX)
includes data from 300 registries in 61 countries. We used data
from volume IX of CI5 and tried to display cross-sectional,
aggregated NPC incidence rates for 1998–2002 for most of the
select registries. The mortality data were abstracted from the death
certificates that were compiled in a WHO mortality database. The
code for NPC according to the International Classification of
Diseases for Oncology (ICD-O) is C11. In CI5, this code is not
individually listed, thus we selected the C09-14 (pharynx) to
approximately represent NPC, while in WHO and GLOBO-
CAN2008 databases, C11 was individually listed to represent
NPC. C09-14 covers all types of pharyngeal cancer that differs
greatly in incidence, risk factors, management and prognosis.
Since there is no study supporting the extrapolation of NPC data
from pharyngeal cancer, we failed to retrieve NPC incidence data
from CI5 database.
For epidemiological and preventive study of medicine, the
tendency of disease incidence and mortality rate are very
important. Joinpoint regression analysis is commonly used for
determining the tendency of disease incidence/mortality based on
the single-year incidence/mortality data with fitting a series of
joined straight lines on a logarithmic scale to the trends in the
annual ASRs annual change [6]. Long time recorded data among
the top 20 countries with the highest mortality rate are abstracted
from WHO mortality database for Joinpoint analysis. Joinpoint
analysis output were expressed as annual percent change (APC) (ie,
the slope of the line segment) [6] and terms ‘‘increase’’ or
‘‘decrease’’ were used when the APC was statistically significant
(P,.05); otherwise the term ‘‘stable’’ was used. Due to the
variability in the economical development and completeness of
health recording system, the quality of long-time recorded data
abstracted from WHO mortality database scored differently, thus
the reliability of tendency analysis varies among NPC entries.
Results
Global differences of NPC incidences
1.1 GLOBOCAN2008 database. Based on the analysis of
2008 data from GLOBOCAN2008 database, the estimated NPC
incidence rates vary markedly worldwide, with ASRs among males
reported to range from 0.2 in Central America to 6.5 per 100,000
person-years in South-Eastern Asia. The majority of registries with
the highest incidence rates of NPC in male were located in Asia,
Micronesia and South Africa. In contrast, the lowest rates were
observed from registries in Central America, Melanesia, Western
Europe, South America and North Europe (Fig. 1, Fig. 2A). At
the national level, NPC incidence rates among males in Malaysia
(11.5), Indonesia (9.4), Singapore (8.3), Taipei of China (7.7),
Brunei (6.5), Guam (6.4), Viet Nam (5.9), Algeria (5.2), South
African Republic (4.9), Cambodia (4.7), Bhutan (4.3), Tunisia (4),
Myanmar (3.9), Morocco (3.7), Thailand (3.6), Lao PDR (3.3),
China (2.8), Sudan (2.8), Kenya (2.6) and Yemen (2.4) rank top 20
all over the world (Fig. 3).
When looking at the case for female population, NPC incidence
rates were reported to range from 0.1 in Central America to 2.8 in
South-Eastern Asia. The majority of registries with the highest
estimations for NPC in female were located in Asia, Micronesia
and South Africa. In contrast, the lowest rates were observed from
registries in Central America, Melanesia, Western Europe, South
America and North Europe (Fig. 1, Fig. 2B). At the national
level, NPC incidence rates among females in Malaysia (4.5),
Bhutan (4.2), Indonesia (3.8), Viet Nam (3.3), Singapore (2.5),
Taipei of China (2.3), Guam (2.1), Myanmar (2.1), Brunei (2),
Yemen (2), Algeria (1.8), South African Republic (1.8), Thailand
(1.8), Tunisia (1.7), Cambodia (1.4), China (1.4), Sudan (1.4), Lao
PDR (1.3), Kenya (1.3) and Morocco (0.9) rank top 20 all over the
world (Fig. 3).
These data reveal that NPC favors male more than female in
that ASRs are twice as high in males as those in females. On the
other hand, the low NPC incidence rate in both male and female
Chinese populations might be the result of dilution by populations
from other registries with low incidence rate. Thus, to look into
more details, the regional registry data are required.
1.2 CI5 database can not be used to retrieve 5-year NPC
incidence rate. However, NPC (C11) is not individually listed
in the current CI5 IX database; the NPC regional incidence rates
can not be retrieved.
The fact that there is no individual category for NPC in CI5
database might reflect that the NPC incidence rates are too low in
most global regions (even in regions of China other than Hong
Kong, Taipei and Guangzhou) to be reported. The health caring
systems in the high incidence regions (majorly in Chinese
population of the developing countries) are not good enough to
cover the epidemiological monitoring of NPC. On the other hand,
Global Variation of Nasopharynx Cancer
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CAN2008 database, it may not reflect the real NPC epidemiology
based on two reasons: first, most of the entries for GLOBO-
CAN2008 database are at the national levels, while for the case of
NPC, it has a significant geographic distribution; second, the
output of GLOBOCAN2008 is based on the estimation from the
current available literature and resources, it is not a real incidence
rate.
1.3 NPC incidence tendency can not be estimated from
CI5 plus database. It would be nice for the prevention purpose
if we can obtain the tendency of NPC incidence. CI5 Plus
database offered annual incidence rate record of some cancers in
some entries and made the tendency analysis with Joinpoint
software possible. Unfortunately, since there is no individual
category for NPC (NPC is cover by an even wider range C00-14)
in this database and most of the high incidence rate entries are not
recorded, we could not analyze the accurate tendency of NPC
incidence rate during the past years.
The fact that individual category for NPC (C11) is not listed
separately in CI5 plus database reflect the reality: 1. NPC is not
prevalent in those entries with well developed cancer registry
systems; 2. Some NPC high incidence entries fails to report the
annual NPC incidence rate because of the less developed cancer
registry systems. For example, Zhongshang and Sihui of
Guangdong province, China are two entries with high NPC
incidence rate [7], unfortunately, they haven’t been included in
the WHO database system and we could not track the NPC
tendency there by using the current CI5 plus database. At the
current stage, CI5 plus database might be very helpful to
investigate the global tendency of some cancer, such as rectal
cancer or lung cancer that is top health threatening to world
population, or some cancer with a well developed international
Figure 1. Continental incidence (red) and mortality (blue) of NPC demonstrated as ASR in 100,000 people-years from
GLOBOCAN2008 database.
doi:10.1371/journal.pone.0022039.g001
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put much more effort in improving the cancer registry system.
Global differences of NPC mortality
Another parameter for cancer epidemiological study is mortal-
ity. Since there is specific category for NPC in both GLOBO-
CAN2008 and WHO mortality databases, we compared the most
recent estimated annual (from GLOBOCAN2008 database) and
real mortalities in 5-year period (from WHO mortality database).
2.1 GLOBOCAN2008 database. In GLOBOCAN2008
database, data under the category of ‘‘nasopharynx cancer
(C11)’’ were collected. NPC mortality rates vary markedly
worldwide, with rates per 100,000 person years among males
reported to range from 0.1 in Central America to 4.2 in South-
Eastern Asia. The majority of registries with the highest incidence
rates of NPC in male were located in Asia, Micronesia and South
Africa. In contrast, the lowest rates were observed from registries
in Central America, Melanesia, Western Europe, South America
and North Europe (Fig. 1, Fig. 4A). At the national level, NPC
mortality rates among males in Brunei (7), Malaysia (6.6),
Indonesia (6), Viet Nam (4.8), Singapore (4.3), Taipei (4.1,
China), Guam (3.7), Algeria (3.4), South African Republic (3.3),
Cambodia (3.2), Bhutan (3.2), Tunisia (2.4), Myanmar (2.4),
Morocco (2.4), Thailand (2.1), Lao PDR (2.1), China (1.9), Sudan
(1.9), Kenya (1.6) and Yemen (1.7) rank top 20 all over the world
(Fig. 3).
NPC mortality rates in female were reported to range from 0.1
in Central America to 1.8 in South-Eastern Asia. The majority of
registries with the highest mortality rates of NPC in female were
located in Asia, Micronesia and South Africa. In contrast, the
lowest rates were observed from registries in Central America,
Melanesia, Western Europe, South America and North Europe
(Fig. 1, Fig. 4B). At the national level, NPC mortality rates
among female in Bhutan (3.6), Malaysia (2.6), Indonesia (2.4), Viet
Nam (2.4), Yemen (1.4), Myanmar (1.3), Taipei (1.2, China),
Algeria (1.2), South African Republic (1.1), Tunisia (1.1), Guam
(1), Thailand (1), Cambodia (0.9), Singapore (0.9), Sudan (0.9),
Lao PDR (0.9), Kenya (0.9), China (0.8), Brunei (0.6) and
Morocco (0.6) rank top 20 all over the world (Fig. 3).
2.2 WHO database (1998–2002). In WHO mortality
database, data under the category of ‘‘nasopharynx cancer
(C11)’’ from 1998–2002 were collected. The analysis output
showed that the entries with top 20 mortality rate in male were
Hong Kong (7.28, China), Singapore (6.64), Malta (1.78),
Hungary (0.59), Slovakia (0.59), Spain (0.57), Greece (0.52),
Israel (0.42), Lithuania (0.37), Estonia (0.37), Czech Republic
(0.36), New Zealand (0.35), Australia (0.33), Canada (0.33),
Croatia (0.32), Mauritius (0.32), Albania (0.31), Republic of
Korea (0.31), Iceland (0.28) and South Africa (0.28) (Fig. 5A).
The entries with top 20 mortality rate in female were Hong Kong
(1.97, China), Singapore (1.83), Malta (.32), Mauritius (0.18),
Estonia (0.16), Spain (0.15), Greece (0.15), Israel (0.14), Albania
(0.14), Hungary (0.13), Australia (0.12), South Africa (0.12),
Lithuania (0.12), Croatia (0.11), Canada (0.11), Czech Republic
(0.11), Slovakia (0.11), Austria (0.11), Unite States of America (0. 1)
and New Zealand (0.1) (Fig. 5B).
When comparing the top-20 mortality rate entries output from
GLOBOCAN2008 and WHO mortality databases, the rank and
ASR values are not consistent. This is because first, the entries for
each database are not same: WHO database includes regional
entries below national level which covers some NPC high
incidence areas like Hong Kong; the entry for GLOBOCAN2008
are basically at nation levels that may dilute the high mortality rate
in a specific region within a country (especially within China).
Second, the calculation protocols used in each database are not
same: GLOBOCAN2008 provides the annual mortality rate
estimation of 2008 while WHO database provides the mortality
rate during 1998–2002. Although differences exist, these two
database outputs together suggested the geographical feature of
NPC that NPC mortality rates are high in south East Asia,
especially some Chinese population in regions like Hong Kong
and Singapore.
2.3 NPC mortality rate trends: Joinpoint analyses of the
available WHO data. Along with the advance of cancer
therapy, we expect that the mortality rate will gradually
decrease. But this is not always true for some specific cancers
(eg. brain and central nervous system cancers). In WHO mortality
database, the annual NPC mortality rate records are available for
some selected entries, and the Joinpoint analysis can be performed
over them to determine the mortality tendency. Since insufficient
women data of annual mortality rate can be obtained from WHO
database for Joinpoint analysis, we tried to abstract available data
from male population in 14 out of the top 20 registries and
checked their NPC mortality tendencies. According to the
literature, the NPC mortality rate is several times higher in old
than in young male population [7], thus we performed Joinpoint
analysis from the all age population and that aged older than
30 years.
Figure 2. GLOBOCAN2008 map for global NPC incidence in male (A) and female (B). Demonstrated as ASR per 100,000 people-years.
doi:10.1371/journal.pone.0022039.g002
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NPC mortality decreased in 8, increased in 1 and kept stable in 5
entries (Table 1). In China Hong Kong, one high incidence
region, mortality rate decrease by 1.5% and 3.6% per year during
the periods of 1966–1983 and 1983–2007, respectively. However,
in another high incidence region, Singapore, mortality rate
increased by 4.2% per year from 1966 through 1976 and then
decrease by 1.9% and 6.1% per year during the periods of 1976–
1996 and 1996–2006, respectively.
Canada and Australia show first increase (by 1.9% per year
during 1955–1988 in Canada and 2.6% per year during 1955–
1990 in Australia) and then decrease (by 2.6% per year during
1988–2004 in Canada and 4.5% per year during 1990–2006 in
Australia). The increase tendency probably can be explained by
the Chinese immigration during this period. These two countries,
with relatively small populations, are among the popular
immigrating countries for Chinese. Before late 1990s, the
immigrated Chinese majorly from south-east China region with
high NPC incidence such as Hong Kong, Taipei and Guangzhou.
The gradually increased mortality rate might be the ‘‘imported’’
effect. While, after the late 1990s, along with the Chinese
reforming and opening policy, more Chinese from NPC low
incidence region move to these two countries. At the same time,
with the changed environment and changed eating habit,
descendents from the first generation Chinese immigrants were
supposed to have a decreased NPC incidence and mortality rates.
Thus, the decreased tendency in these two countries can be
observed in the past 2 decades. To confirm this hypothesis, more
detailed population studies in these countries are needed.
Greece is the only one country showed constant increase of NPC
mortality rate by 2.2% per year from 1966 through 2008. While,
when taken the ASR from each entry into consideration (0.52 ASR
per 100,000 person years in Greece), the increase may not explain
anything. The situation in Greece needs more observation.
When Joinpoint analysis was performed in the population of
older than 30 years, similar tendencies for each entry can be
observed (Table 2). This supported that the NPC mortality
tendency was majorly contributed by this population group with
age older than 30 years.
In our analysis, the available entry period of WHO mortality
database varied from 12 to 50 years (median 29 yr), it is highly
possible that a shorter entry period may not reveal the real
tendency. To check the tendency within a fixed long period, we
selected 5 entries with longer entry period that represent decreased
tendency with high (China Hong Kong and Singapore) or low
(Australia and Canada) morality rate as well as increased tendency
Figure 3. National incidence (red) and mortality (blue) of NPC demonstrated as ASR per 100,000 people-years from
GLOBOCAN2008 database.
doi:10.1371/journal.pone.0022039.g003
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the Joinpoint analysis was performed. This further analysis did not
change the conclusions obtained by previous analysis and the
curves for Joinpoint analysis from these entries were offered as
examples (Fig. 6).
Discussion
Based on the integrated analyses of GLOBOCAN and WHO
databases, we described that NPC showed a racial/ethnic and
geographic distribution that South-east Asia, especially Hong
Kong and Guangdong province of China are with highest
incidence and mortality rates. During the past several decades,
the mortality rates of the top 20 ranked regions showed decrease
tendencies. However, since NPC is not individually list in CI5 and
CI5 plus databases, we failed to retrieve the 5-year NPC incidence
and incidence tendency, respectively. Due to the incomplete
cancer entries in those NPC high incidence regions (for all three
databases), cautions should be put when explain our data.
1. Varied database quality limited the high quality output
1.1. NPC accounts for the majority of pharynx cancers in
high incidence rate regions. Since incidence rates of pharynx
cancer (C09-14) instead of NPC (C11) were collected from CI5
and CI5 plus databases, one very important issue is to address
whether these incidence rates of pharynx cancer can reflect NPC
Figure 4. GLOBOCAN2008 map for global NPC mortality rate in male (A) and female (B). Demonstrated as ASR per 100,000 people-years.
doi:10.1371/journal.pone.0022039.g004
Figure 5. Regional mortality of NPC (C11) demonstrated as ASR from WHO mortality database of male (A) and female (B)
populations.
doi:10.1371/journal.pone.0022039.g005
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or GLOBOCAN2008 databases with epidemiological data from
individual regions, we found that incidence output from CI5 and
GLOBOCAN2008 databases are quite similar with regional
reports from the high incidence region such as Malaysia [8],
Singapore [9,10], China Hong Kong [10,11], etc. But this is not
true for some countries/regions that are known to have a low NPC
incidence rates such as France [12] and Australia [13]. For
example, according to the CI5 output, several regions from France
rank within top 10 highest incidence rates in case of pharynx
cancer, while this is not true when we obtained data for NPC itself
from GLOBOCAN2008. These finding confirmed that the
geographic distribution of NPC: in those high incidence rate
regions, NPC accounts for the majority of pharynx cancer; while
in those low incidence rate regions, NPC accounts for a very little
portion of pharynx cancer.
Table 1. NPC mortality rate trends in all age male population with Joinpoint analyses on the available data of the 14 out of the top
20 mortality rate registries.
Trend 1 Trend 2 Trend 3
years APC [95% CI] years APC [95% CI] years APC [95% CI]
0–85+ years
China Hong Kong 1966–1983 21.5*[22.4 – 20.68] 1983–2007 23.6* [24.1 – 23.2]
Singapore 1966–1976 4.2* [0.7 – 7.8] 1976–1996 21.9* [22.9 – 20.9] 1996–2006 26.1* [28.4 – 23.7]
Malta 1978–2007 22.3 [24.6 – 0.1] 1999–2007 210.1 [224.0 – 6.4]
Slovakia 1992–2005 22.9* [25.7 – 20.1]
Greece 1966–2008 2.2* [1.5 – 2.9]
Isreal 1975–2006 21.4* [22.7 – 20.1]
Lithuania 1993–2008 2.2 [22.1 – 6.7]
Czech Republic 1986–2008 22.3* [23.8 – 20.8]
Australia 1955–1990 2.6* [1.7 – 3.5] 1990–2006 24.5* [26.3 – 22.6]
Canada 1955–1988 1.9* [1.3 – 2.5] 1988–2004 22.6* [24.0 – 21.3]
Croatia 1985–2008 22.4 [25.0 – 0.3]
Albania 1987–2004 26.5* [29.9 – 23.0]
South Africa 1993–2006 20.3 [24.7 – 4.3]
USA 1960–1998 20.8* [21.1 – 20.5] 1998–1999 231.1 [2– 2] 1999–2005 20.0 [23.9 – 4.1]
*The average APC is statistically significant from zero.
doi:10.1371/journal.pone.0022039.t001
Table 2. NPC mortality rate trends in population older than 30 years with Joinpoint analyses on the available data of the 14 out of
the top 20 mortality rate registries.
Trend 1 Trend 2 Trend 3
years APC [95% CI] years APC [95% CI] years APC [95% CI]
China Hong Kong 1966–1983 21.4*[22.3 – 20.5] 1983–2007 23.6* [24.0 – 23.2]
Singapore 1966–1975 4.9* [20.8 – 9.1] 1975–1995 21.6* [22.6 – 20.6] 1995–2006 25.8* [27.7 – 23.8]
Malta 1978–2007 22.3 [24.6– 20.1]
Slovakia 1992–2005 22.9 [26.3 – 0.5]
Greece 1966–2008 2.0* [1.3 – 2.7]
Isreal 1975–2006 21.4* [22.7 – 20.1]
Lithuania 1993–2008 1.8 [22.9 – 6.6]
Czech Republic 1986–2008 22.2* [23.7 – 20.6]
Australia 1955–1992 2.6* [1.9– 3.4] 1992–2006 26. 1* [28.4– 23.8]
Canada 1955–1988 1.8* [1.0 – 2.5] 1988–2004 22.1* [23.6 – 20.6]
Croatia 1985–2008 22.4 [24.9 – 0.2]
Albania 1987–2004 27.4* [210.7 – 24.0]
South Africa 1994–2006 1.2 [22.8 – 5.4]
USA 1960–1983 20.1 [20.6 – 0.4] 1983–2005 21.8[22.2 – 21.4]
*The average APC is statistically significant from zero.
doi:10.1371/journal.pone.0022039.t002
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mortality rates and possible reasons. NPC is not a disease
of modern environmental hazards since ancient China [14] and
Egypt [15] had already demonstrated higher incidence and
mortality; it is rather, closely related with genetic and/or stable
environmental risk factors that may have persisted for centuries.
According to modern cancer registry data, NPC incidence has
remained high in Southeast Asia for several decades [16,17].
However, significant steady declines in incidence and mortality has
occured in Hong Kong since the 1970s [11,16], in Taiwan since
the 1980s [17], and in Singapore Chinese since the late 1990s
[1,2]. Such a drastic change may be attributable to the onset of
rapid economic development, which occurred in the mid-1940s in
Hong Kong, the 1950s in Taiwan, and the 1960s in Singapore
[14]. On the other hand, the incidence rate of NPC increased
among Singapore Malays between 1968 and 1997 [18], and
remained steady or increased slightly (among males in Cangwu
county of Guangzhou city) in Southeastern China between 1978/
1983 and 2002 [7].
1.3 Limitations of the current findings. The analysis from
GLOBOCAN database suggested that the highest incidence rates
are in the southeast of China. In almost all populations surveyed,
the incidence of NPC is 2- to 3-fold higher in males than in
females and this is consistent with previous report [1]. However,
the current findings were limited majorly because of the varied
database qualities in cancer entry systems. Highest NPC incidence
has been reported among people of Guangdong province and
Guangxi region of China where the incidence of NPC reaches 50
or more per 100000 person years [19]. Unfortunately, these two
provinces are not included into the GLOBOCAN2008 database.
The NPC incidence rates in male and females of Naga, India
account for 6.2 and 2.1 per 100,000 person-years, respectively
[20,21], this region is not listed within top 20 high incidence rate
regions probably because of the developing cancer entry system
there.
Our findings can not reflect the fact that the high NPC
incidence rates stick to high risk population did not change even
after they migrate to lower-risk countries. Indeed, among southern
Chinese living in Singapore, Malaysia, and Japan, NPC rates are
comparable with those in natives of southern China [1,22,23].
Likewise, NPC incidence is higher in North African migrants to
Israel and their offspring than in native Israelis [24]. The inter
country comparison of NPC incidence rate between different
ethnics groups from the GLOBOCAN2008 database could not be
performed because of the limited cancer registries.
2. What can be learned from the current study?
2.1. The usability of this analysis for different
cancer. Although the combined analysis on CIN databases
(CI5, GLOBOCAN and WHO) has been succeeded in giving an
international view on some specific cancer type [5], it may not be
much usable for a cancer with specific ethnic/geographic
distributions at the current version, especially when it is specific
for the economically transition countries/regions. First, the cancer
entry systems in the economically transition countries/regions are
mostly under developing and may not cover all the cancers and
sub regions, thus the output database quality might be low.
Second, if a cancer that is restricted to a specific population or
specific region, it may not appeal to the international interest for
cancer research and therapy. This attitude may bias the enrolled
data of this specific cancer.
2.2 More effort should be put in developing the cancer
entry system all over the world to offer detailed and
accurate data for most cancers. Cancer with specific
ethnic/geographic distribution may not affect most population
all over the world, but it is a real devastating tragedy for those
being affected who can be the major population of the specific
region or ethnics. Thus, it has very important meaning to
understand the epidemiology of the specific cancer. To offer more
useful information, lots of effort should be put in developing the
regional cancer entry system, especially in the economically
transition countries.
Actually, CIN keeps offering efforts to help local healthy agencies
improve the cancer entry system in order to finally increase the
worldwide coverage of cancer registry. These activities include
providing administrative facilities and a secretariat to the Interna-
tional Association of Cancer Registries (IACR, www.iacr.com.fr)
and to the European Network of Cancer Registries (ENCR, www.
encr.com.fr). CIN staffs are involved in conducting site visits to
assess the feasibility of establishing new cancer registries and to
provide developmental advice to existing registries, particularly in
low and middle income countries. CIN arranges training courses on
cancer registration and its application to epidemiology. CIN has
also developed the CanReg5 software package, now used in more
than 50 countries, and provides training in its use. Alongside the
above activities, CIN conducts a program of research focused on
descriptive epidemiology. Core components include the study of
temporal trends and patterns in the occurrence of and outcomes
from cancer, as well as the development of methodological
approaches to their analysis.
Combining the efforts from CIN and local healthy agencies,
high quality CIN databases are expected that more reliable
analysis of international tendencies of most cancer types can be
performed.
Supporting Information
Figure S1 Regional incidence of pharyngeal cancer during
1998-2002 demonstrated as ASR per 100,000 person years from
CI5 database (ICD 10 code: C09-14) of male (left) and female
(right) populations.
(TIF)
Figure 6. Representative joint point analysis output from NPC
mortality data of China Hong Kong, Singapore, Greece,
Australia and Canada. Dots represent observed value and lines
represent modeled data. In this analysis, two join points were set.
doi:10.1371/journal.pone.0022039.g006
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